← Back to Clinical Trials
Recruiting NCT05622344

NCT05622344 StableEyes With Active Neurofeedback

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05622344
Status Recruiting
Phase
Sponsor Johns Hopkins University
Condition Vestibular Disorder
Study Type INTERVENTIONAL
Enrollment 48 participants
Start Date 2022-08-08
Primary Completion 2026-09-30

Eligibility & Interventions

Sex All sexes
Min Age 21 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Traditional TherapySWAN

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 48 participants in total. It began in 2022-08-08 with a primary completion date of 2026-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The investigators have developed a self-administered rehabilitation tool that incrementally guides the user to increase head motion to mitigate motion sickness and enhance postural recovery following centrifugation or unilateral vestibular nerve deafferentation surgery.

Eligibility Criteria

Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. In good general health as evidenced by medical history or diagnosed with unilateral vestibular schwannoma 4. Willing to adhere to the SWAN and/or vestibular rehabilitation regimen Exclusion Criteria: 1. Current use of anti-nausea medication 2. Presence of cervical spine pathology that limits head motion to \< 30 degrees in the horizontal or vertical plane (i.e. degenerative disc disease, rheumatoid arthritis) 3. Any orthopedic pathology that prevents walking or standing independently (i.e. recent surgery) 4. Legal blindness (20/200 or worse visual acuity) 5. Treatment using a motion sickness investigational drug or other motion sickness behavioral intervention within 30 days

Contact & Investigator

Central Contact

Michael Schubert, PhD

✉ mschube1@jhmi.edu

📞 4108427403

Principal Investigator

Matthew Stewart, MD PhD

PRINCIPAL INVESTIGATOR

Johns Hopkins University

Frequently Asked Questions

Who can join the NCT05622344 clinical trial?

This trial is open to participants of all sexes, aged 21 Years or older, up to 70 Years, studying Vestibular Disorder. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05622344 currently recruiting?

Yes, NCT05622344 is actively recruiting participants. Contact the research team at mschube1@jhmi.edu for enrollment information.

Where is the NCT05622344 trial being conducted?

This trial is being conducted at Baltimore, United States, Dayton, United States.

Who is sponsoring the NCT05622344 clinical trial?

NCT05622344 is sponsored by Johns Hopkins University. The principal investigator is Matthew Stewart, MD PhD at Johns Hopkins University. The trial plans to enroll 48 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology